Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Matsuyama
Clinical trial register · Japan

Clinical Trials in Matsuyama, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Fukuoka 551 Nagoya 517 Sapporo 398 Tokyo 369 Osaka 348
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC19 AstraZeneca19 Pfizer12 Bristol-Myers Squibb10 Amgen10
Site location
Fukuoka551 Nagoya517 Sapporo398 Tokyo369 Osaka348
All 926 locations
Target enrolment
to

Trials with a site in Matsuyama

171 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
Pfizer
Phase 3
180
Chiba, Matsuyama, Fukuoka, Kasuya-gun, Sapporo, Amagasaki, Mito, Naka
2026-10-02
Recruiting
Amgen
Phase 3
950
Matsuyama, Kitakyusyu-shi, Aki-gun, Mito, Naka, Tsuchiura-shi, Kumamoto, Kashiwara-shi
2026-07-29
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Chiba, Fukuoka, Gunma, Kamakura-shi, Kyoto, Matsuyama, Okayama, Sapporo
2026-05-31
Recruiting
AbbVie
Phase 3
990
Kashiwa-shi, Matsuyama, Kobe, Kawasaki-shi, Osaka, Koto-ku
2026-05-22
Recruiting
Bristol-Myers Squibb
Phase 2/3
690
Nagoya, Chiba, Kashiwa, Matsuyama, Yokohama, Kurashiki, Osaka, Suita
2026-03-13
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Kashiwa, Matsuyama, Fukuoka, Kashihara-shi, Sakai, Suita, Bunkyo-ku, Koto
2026-02-17
Recruiting
Eli Lilly and Company
Phase 3
900
Chūōku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka
2026-02-10
Recruiting
Bristol-Myers Squibb
Observational
150
Chiba, Kashiwa-shi, Sakura, Matsuyama, Chikushino-shi, Fukuoka, Asahikawa, Sapporo
2026-01-29
Recruiting
Generate Biomedicines
Phase 3
786
Seto-shi, Matsuyama, Fukui-shi, Iizuka-Shi, Isesaki-Shi, Hiroshima, Asahikawa-shi, Himeji
2026-01-20
Recruiting
AbbVie
Phase 2/3
680
Nagoya, Matsuyama, Kurume-shi, Isehara, Kyoto
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Asahikawa, Sapporo, Kobe
2026-01-06
Recruiting
Bristol-Myers Squibb
Phase 2/3
990
Nagoya, Toyoake, Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Yokohama
2025-12-31
Recruiting
AstraZeneca
Phase 2
320
Aomori, Bunkyō City, Fukuoka, Hamamatsu, Hitachi-Naka, Iizuka-shi, Kawachinagano-shi, Matsuyama
2025-12-15
Recruiting
Incyte Corporation
Phase 3
466
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Minatoku, Nagoya, Okayama
2025-12-09
Recruiting
AstraZeneca
Phase 3
1,100
Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi
2025-12-04
Recruiting
Amgen
Phase 3
750
Nagoya, Matsuyama, Fukuoka, Kobe, Kanazawa, Kita-gun, Sagamihara-shi, Osaka
2025-11-28
Recruiting
Incyte Corporation
Phase 2
160
Akashi-shi, Hidaka-shi, Kōtoku, Kurume, Matsuyama, Sapporo, Sunto-gun
2025-11-12
Recruiting
AstraZeneca
Phase 3
420
Akashi, Bunkyō City, Himeji-shi, Kōtoku, Kumamoto, Matsumoto-shi, Matsuyama, Meguro-ku
2025-11-11
Recruiting
AstraZeneca
Phase 3
400
Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama
2025-10-31
Recruiting
Pfizer
Phase 3
1,000
Chiba, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka, Suita
2025-09-28
Recruiting
Sanofi
Phase 3
942
Kōnan, Nagoya, Toyota, Matsuyama, Fukuoka, Iizuka, Kurume, Kure
2025-09-16
Recruiting
Bristol-Myers Squibb
Phase 2/3
600
Nagoya, Chiba, Matsuyama, Otashi, Sapporo, Kanazawa, Isehara, Yokohama
2025-09-11
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
DrugsCasdatifan·Cabozantinib
Arcus Biosciences, Inc.
Phase 3
720
Akita, Asahikawa, Fukuoka, Hidaka, Hiroshima, Kobe, Matsuyama, Nagoya
2025-09-08
Recruiting
BeOne Medicines
Phase 3
500
Nagoya, Nakamuraku, Matsuyama, Fukushima, Hiroshima, Sapporo, Nankoku, Kumamoto
2025-09-04
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
Bunkyō City, Fukuoka, Gifu, Hidaka, Kanazawa, Kashiwa, Kobe, Matsuyama
2025-09-02
Recruiting
BeOne Medicines
Phase 3
351
Matsuyama, Kitakyushu, Sapporo, SakaiShi, Takatsukishi, Kitaadachigun, Hamamatsushi, Utsunomiya
2025-08-27
Active, closed
Amgen
Phase 3
350
Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Niigata, Okayama, Hirakata-shi
2025-08-18
Recruiting
Pfizer
Phase 3
400
Chiba, Kashiwa, Matsuyama, Otashi, Isehara, Yokohama, Suita, Bunkyo-ku
2025-08-05
Recruiting
AstraZeneca
Phase 3
800
Chūōku, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kōtoku, Kurume-shi, Matsuyama, Minatoku
2025-08-01
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Matsuyama, Sapporo, Tsu, Hirakata, Sakai, Hidaka, Sunto-gun
2025-07-21
Active, closed
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033Primary Myelofibrosis, Myeloproliferative Neoplasm
DrugBesremi
PharmaEssentia
Phase 3
160
Kamogawa, Matsuyama, Hiroshima, Morioka, Kamakura, Tsu, Miyazaki, Hirakata
2025-07-18
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Nagoya, Matsuyama, Sapporo, Kahoku-gun, Yokohama, Tsu, Naha, Hirakata
2025-06-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Nagoya, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Akashi, Shiwa-gun
2025-05-22
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsZolbetuximab·Adrucil·Capecitabine·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
500
Chiba, Kashiwa, Matsuyama, Fukuoka, Maebashi, Sapporo, Akashi-shi, Kobe
2025-05-22
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
DrugsCetuximab·Docetaxel
Revolution Medicines, Inc.
Phase 3
590
Nagoya, Toyoake-shi, Kashiwa-shi, Matsuyama, Sapporo, Akashi, Kanazawa, Sagamihara
2025-05-06
Active, closed
Eli Lilly and Company
Phase 3
487
Chūōku, Kamakura-shi, Matsuyama, Yamato-shi
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Chūōku, Kamakura-shi, Matsuyama, Yamato-shi
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
974
Chūōku, Kamakura-shi, Matsuyama, Yamato-shi
2025-04-30
Recruiting
BeOne Medicines
Phase 3
250
Nagoya, Chiba, Matsuyama, Hiroshima, Sapporo, AmagasakiCity, Kagoshima, KyotoShi
2025-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Shiwa-gun
2025-04-09
Recruiting
Daiichi Sankyo
Phase 3
510
Chūōku, Hiroshima, Kashiwa, Kita-gun, Kobe, Kōtoku, Matsuyama, Nagoya
2025-03-27
Active, closed
Amgen
Phase 3
1,105
Matsuyama, Kitakyusyu-shi, Aki-gun, Mito, Naka, Tsuchiura-shi, Kumamoto, Kashiwara-shi
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Nagoya, Kashiwa, Matsuyama, Sapporo, Kahoku-gun, Isehara, Kawasaki, Sagamihara
2025-03-16
Recruiting
BeOne Medicines
Phase 3
300
Nagoya, Toyohashishi, Chiba, Matsuyama, Ōgaki, Hiroshima, Sapporo, KobeShi
2025-03-05
Recruiting
Bristol-Myers Squibb
Phase 3
530
Matsuyama, Kurume, Sapporo, Kobe, Kanazawa, Yokohama, Sendai, Kashihara
2025-02-25
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin
AstraZeneca
Phase 1/2
408
Kōtoku, Matsuyama, Nagoya
2025-01-30
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,046
Nagoya, Kashiwa, Matsuyama, Kobe, Kanazawa, Isehara, Sendai, Sakai
2025-01-27
Active, closed
Amgen
Phase 3
707
Nagoya, Kashiwa-shi, Matsuyama, Maebashi, Sapporo, Kanazawa, Sagamihara-shi, Yokohama
2024-12-09
Active, closed
Genmab
Phase 3
191
Matsuyama, Kitakyushu-shi, Hiroshima, Kobe, Kumamoto, Osakasayama-shi, Bunkyō City, Chūōku
2024-11-25
Recruiting
Pfizer
Phase 3
900
Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka
2024-10-22
Active, closed
Pfizer
Phase 3
600
Chiba, Kashiwa, Matsuyama, Sapporo, Kobe, Kanazawa, Yokohama, Yokosuka
2024-10-21
Recruiting
Ferring Pharmaceuticals
Phase 3
454
Nagakute, Nagoya, Narita, Matsuyama, Fukuoka, Hiroshima, Kobe, Hitachi
2024-10-01
Active, closed
Genmab
Phase 3
379
Toyoake, Matsuyama, Fukuoka, Fukushima, Sapporo, Amagasaki, Kagoshima, Isehara
2024-08-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
686
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ohta, Sapporo, Tsukuba
2024-07-24
Recruiting
Jazz Pharmaceuticals
Phase 3
286
Nagoya, Chiba, Kashiwa, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kagoshima
2024-07-19
Recruiting
Amgen
Phase 3
450
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Akashi-shi, Kawasaki-shi
2024-07-17
Recruiting
Guangzhou Virotech Pharmaceutical Co., Ltd.
Phase 1
12
Kashiwa-shi, Matsuyama, Kawasaki-shi
2024-07-10
Active, closed
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3
464
Kashiwa-shi, Matsuyama, Gifu, Ota-Shi, Kure, Sapporo, Fukuoka, Akashi
2024-06-30
Active, closed
Amgen
Phase 3
563
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Sapporo, Akashi-shi, Yokohama
2024-06-05
Recruiting
Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)
NCT06436092Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
TCROSS Co., Ltd.
Observational
280
Ichinomiya, Toyoake, Chiba, Matsudo, Urayasu, Matsuyama, Fukuoka, Kitakyushu
2024-05-27
Recruiting
Daiichi Sankyo
Phase 3
540
Chūōku, Fukuoka, Hirakata-shi, Kashiwa, Kōtoku, Matsuyama, Nakatogari, Okayama
2024-05-21
Active, closed
Takeda
Phase 1/2
28
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Akashi, Shiwa-gun, Sendai
2024-05-20
Recruiting
Daiichi Sankyo
Phase 1/2
680
Nagoya, Kashiwa, Matsuyama, Ōsaka-sayama, Nagaizumi-cho, Chuo-ku, Koto-ku, Saitama
2024-04-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
780
Kashiwa, Matsuyama, Kitakyushu, Kobe, Kawasaki, Yokohama, Hirakata, Sakai
2024-04-03
Recruiting
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
NCT06172478Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
740
Hidaka, Kanagawa, Kashiwa-shi, Matsuyama, Nagaizumi-cho, Nagoya, Osakasayama-shi, Saitama
2024-02-26
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
762
Nagoya, Kashiwa-shi, Matsuyama, Kurume, Ota-Shi, Kobe, Kanazawa, Yokohama
2024-02-21
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Yokohama, Sendai, Niigata
2024-02-20
Recruiting
Pfizer
Phase 3
492
Toyohashi, Matsuyama, Maebashi, Shibukawa, Kobe, Shiwa-gun Yahaba-cho, Bunkyo-ku, Koto
2024-02-08
Active, closed
Genmab
Phase 3
1,095
Toyoake, Matsuyama, Yoshida-gun, Fukuoka, Fukuyama, Sapporo, Kobe, Hitachi-shi
2024-02-05
Recruiting
A Study of KK2269 in Adult Participants With Solid Tumors
NCT06266299Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
DrugDocetaxel
Kyowa Kirin Co., Ltd.
Phase 1
101
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Kobe, Yokohama, Hirakata
2024-01-18
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 2
226
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Yahatanishi-ku, Kitakyusyu-shi, Ota-shi, Hiroshima, Akashi-shi
2024-01-10
Active, closed
Bristol-Myers Squibb
Phase 3
190
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sendai, Bunkyo Ku, Yonago
2023-12-21
Recruiting
Merck Sharp & Dohme LLC
Phase 3
614
Toyoake, Hirosaki, Kashiwa, Matsuyama, Fukuoka, Kurume, Ōta, Himeji
2023-12-15
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Nagoya, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun
2023-12-06
Active, closed
AbbVie
Observational
250
Matsuyama, Asahikawa, Hakodate-shi, Ryūgasaki, Tsukuba, Kagoshima, Kyoto, Sendai
2023-11-30
By invitation
Shanghai Henlius Biotech
Phase 1
367
Sendai, Sayama, Matsuyama, Okayama, Shizuoka, Tokyo
2023-11-24
Recruiting
Amgen
Phase 3
750
Nagoya, Hirosaki-shi, Chiba, Kashiwa-shi, Matsuyama, Toon-shi, Fukuoka, Kitakyushu-shi
2023-11-16
Active, closed
Merck Sharp & Dohme LLC
Phase 3
556
Nagoya, Toyoake, Kashiwa, Matsuyama, Otashi, Takarazuka, Kanazawa, Yokohama
2023-11-12
Active, closed
BeOne Medicines
Phase 3
652
Nagoya, Chiba, Matsuyama, Sapporo, AmagasakiCity, Kagoshima, Iseharashi, Sendai
2023-11-11
Active, closed
AstraZeneca
Phase 3
863
Amagasaki-shi, Hakodate-shi, Hiroshima, Kitaadachi-gun, Kitakyushu-shi, Matsuyama, Nagoya, Nishinomiya-shi
2023-11-09
Recruiting
Kyowa Kirin Co., Ltd.
Phase 1
189
Nagoya, Kashiwa, Matsuyama, Hiroshima, Kobe, Yokohama, Kumamoto, Sendai
2023-11-01
Active, closed
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
NCT06049212Non-small Cell Lung Cancer, Solid Tumors, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)
DrugsSacituzumab tirumotecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
30
Nagoya, Kashiwa, Matsuyama, Yokohama, Hirakata, Nagaizumi-cho,Sunto-gun, Chuo-ku
2023-10-26
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,109
Nagakute, Abiko, Kashiwa, Sakura, Matsuyama, Kitakyushu, Kurume, Maebashi
2023-10-25
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Fukuoka, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Okayama
2023-10-24
Recruiting
NRG Oncology
Phase 3
3,960
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2023-10-18
Active, closed
Servier
Phase 2
12
Kashiwa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo, Yokohama
2023-10-10
Recruiting
AstraZeneca
Phase 3
800
Fukuoka, Ginowan-shi, Hidaka-shi, Kagoshima, Kōtoku, Kurume-shi, Maebashi, Matsuyama
2023-09-22
Recruiting
Hoffmann-La Roche
Phase 3
230
Aichi, Chiba, Hiroshima, Kagoshima, Kanagawa, Kyoto, Matsuyama, Saitama
2023-09-08
Active, closed
AstraZeneca
Phase 3
111
Kanazawa, Kashiwa, Matsuyama, Musashino-shi, Osakasayama-shi, Yokohama
2023-06-27
Active, closed
Amgen
Phase 3
509
Nagoya, Kashiwa-shi, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yokohama, Sendai
2023-05-31
Active, closed
Servier Affaires Médicales
Phase 3
299
Kanagawa, Kumamoto, Matsuyama, Osaka, Sapporo, Tokyo
2023-05-03
Active, closed
AbbVie
Phase 3
520
Nagoya, Chiba, Kashiwa, Matsuyama, Kurume-shi, Sapporo, Akashi-shi, Yahaba
2023-03-15
Active, closed
Genmab
Phase 3
900
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe, Tsukuba
2023-02-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
614
Nagoya, Matsuyama, Kurume, Takarazuka, Kanazawa, Yokohama, Natori-shi, Sendai
2023-02-06
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Toyohashi, Kashiwa-shi, Matsuyama, Chikushino-shi, Iizuka-shi, Kurume-shi, Ota-shi, Fukuyama-shi
2023-01-16
Active, closed
Novartis Pharmaceuticals
Phase 3
90
Narita, Matsuyama, Gifu, Kobe, Isehara, Suita, Itabashi-ku, Shinjuku Ku
2022-12-30
Active, closed
Ferring Pharmaceuticals
Phase 3
25
Nagakute-shi, Nagoya, Narita-shi, Matsuyama, Fukuoka, Hiroshima, Hakodate-shi, Sapporo
2022-12-21
Active, closed
AbbVie
Phase 1
288
Kashiwa-shi, Matsuyama, Sapporo, Kyoto, Sunto-gun, Chuo-ku, Koto-ku, Wakayama
2022-12-05
Recruiting
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
400
Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kobe, Kita-gun, Kawasaki-shi
2022-10-24
Active, closed
Genmab
Phase 3
549
Nagoya, Toyoake, Kashiwa-shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Kobe
2022-09-20
Active, closed
AstraZeneca
Phase 3
594
Bunkyō City, Chūōku, Kōtoku, Kurashiki-shi, Kurume-shi, Matsuyama, Nagoya, Niigata
2022-09-15
Active, closed
Celgene
Phase 3
939
Matsuyama, Higashi-Ibaraki-gun, Shimotsuga, Nerima-ku, Shinagawa-ku, Chuo-shi, Aomori, Chiba
2022-06-23
Recruiting
Astellas Pharma Inc
Phase 1
681
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Yokohama, Sendai, Niigata
2022-06-08
Active, closed
Merck Sharp & Dohme LLC
Phase 3
460
Nagoya, Kashiwa, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai
2022-03-24
Active, closed
BeOne Medicines
Phase 3
799
Matsuyama, Hiroshima, Sapporo, Kagoshima, Yokohama, KyotoShi, Okayama, Hirakata
2022-03-10
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
654
Kamogawa, Kashiwa-Shi, Matsuyama, Fukuoka, Fukushima, Sapporo, Tsukuba, Kanazawa
2022-03-07
Active, closed
Daiichi Sankyo
Phase 3
740
Aomori, Kashiwa-shi, Matsuyama, Fukuoka, Kurume-shi, Kanazawa, Yokohama, Kumamoto
2022-03-04
Active, closed
GlaxoSmithKline
Phase 3
21
Nagoya, Kamogawa, Kashiwa, Matsuyama, Fukushima, Maebashi, Shibukawa, Numakunai
2022-02-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
280
Kashiwa, Matsuyama, Tōon, Kurume, Otashi, Sapporo, Tsukuba, Shiwa-gun Yahaba-cho
2022-02-03
Active, closed
Bristol-Myers Squibb
Phase 2
19
Nagoya, Toyoake, Aomori, Kamogawa, Kashiwa-shi, Matsuyama, Yoshida Gun, Fukuoka
2022-01-17
Active, closed
Merck Sharp & Dohme LLC
Phase 3
643
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Shiwa-gun Yahaba-cho, Kawasaki
2021-12-13
Active, closed
AstraZeneca
Phase 3
454
Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai
2021-10-28
Recruiting
Bayer
Phase 1/2
430
Nagoya, Kashiwa, Matsuyama, Sapporo, Yokohama, Sakai, Sunto, Chuo-ku
2021-10-25
Active, closed
Haihe Biopharma Co., Ltd.
Phase 2
93
Kurume, Suita, Chuo Ku, Minato-Ku, Shinjuku-Ku, Matsuyama, Nagoya, Niigata
2021-10-11
Active, closed
Eli Lilly and Company
Phase 3
874
Nagoya, Chiba, Matsuyama, Kurume, Otashi, Sapporo, Akashi, Kobe
2021-10-04
Active, closed
GlaxoSmithKline
Phase 3
24
Aomori, Fukuoka, Himeji, Kamakura, Kitakyushu, Kochi, Matsuyama, Nagoya
2021-07-28
Active, closed
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Recruiting
NRG Oncology
Phase 3
1,670
Tōon, Sapporo, Akashi, Gunma, Koto-ku, Hiroshima, Kyoto, Matsuyama
2021-06-23
Active, closed
Daiichi Sankyo
Phase 1
246
Matsuyama, Fukuoka, Sapporo, Yokohama, Okayama, Chuo Ku, Iwakuni-shi, Ōsaka-sayama
2021-06-11
Active, closed
Daiichi Sankyo
Phase 3
490
Nagoya, Chūōku, Gifu, Kashiwa, Kobe, Kochi, Kōtoku, Matsuyama
2021-05-21
Active, closed
Pfizer
Phase 3
599
Nagoya, Hirosaki, Chiba, Kashiwa, Matsuyama, Fukuoka, Kure, Sapporo
2021-05-12
Active, closed
Pfizer
Phase 2
66
Nagoya, Kashiwa, Matsuyama, Sapporo, Akashi, Nishinomiya, Tsukuba, Yokohama
2021-04-08
Active, closed
AbbVie
Phase 1
81
Nagoya, Kashiwa-shi, Matsuyama, Fukuoka, Chuo-ku
2021-02-23
Active, closed
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04619004Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
DrugPatritumab deruxtecan
Daiichi Sankyo
Phase 2
277
Kashiwa, Tokyo, Matsuyama, Sapporo, Akashi, Chiba, Ariake, Sendai
2021-02-02
Active, closed
Genmab
Phase 3
483
Fukuoka, Fukushima, Fukuyama, Hokkaido, Kashiwa, Kyoto, Matsuyama, Mie
2021-01-13
Active, closed
Merck Sharp & Dohme LLC
Phase 3
990
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Ōta, Sapporo, Akashi
2021-01-10
Active, closed
Daiichi Sankyo
Phase 1
179
Chuo Ku, Kashiwa-shi, Fukuoka, Kōtoku, Matsuyama, Nakatogari, Saitama
2020-12-22
Active, closed
Kyowa Kirin Co., Ltd.
Phase 2
61
Anjo, Nagoya, Kamogawa, Matsuyama, Maebashi, Fukuyama, Sapporo, Kanazawa
2020-09-17
Active, closed
ADC Therapeutics S.A.
Phase 3
440
Nagoya, Toyohashi, Kashiwa, Matsuyama, Ōta, Sapporo, Kobe, Yokohama
2020-09-16
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 2
70
Chiba, Kashiwa, Matsuyama, Fukuoka, Kurume, Hiroshima, Sapporo, Akashi
2020-09-10
Active, closed
AstraZeneca
Phase 3
805
Chūōku, Kashiwa-shi, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Minatoku, Nagoya
2020-05-05
Active, closed
Janssen Pharmaceutical K.K.
Phase 2
31
Chūōku, Fukuoka, Hirakata, Matsuyama, Nagoya, Niigata, Sapporo
2020-04-07
Active, closed
Takeda
Phase 3
354
Toyoake-Shi, Kashiwa-Shi, Matsuyama, Sapporo, Kurume-Shi, Yokohama, Kumamoto, Natori-shi
2020-01-10
Active, closed
Pfizer
Phase 3
1,068
Matsuyama, Tōon, Fukuoka, Ōta, Sapporo, Yokohama, Osaka, Sakai
2019-12-30
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Kobe, Isehara-Shi, Kyoto
2019-11-13
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
466
Nagoya, Kashiwa, Hiroshima, Matsuyama, Fukuoka, Sapporo, Nishinomiya, Tsukuba
2019-10-02
Active, closed
Multicentre Registry of CCTA, IVUS and OCT
NCT04066062Coronary Artery Disease
Cleerly, Inc.
Observational
1,700
Ehime, Hiroshima, Matsuyama, Okayama, Tokyo
2019-10-01
Recruiting
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
NCT04064060Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
DrugLuspatercept
Celgene
Phase 3
665
Nagoya, Kamogawa, Matsuyama, Ōgaki, Himeji, Hitachi, Sagamihara, Sendai
2019-08-12
Recruiting
Bristol-Myers Squibb
Phase 2
1,500
Hirosaki-shi, Chiba, Kashiwa-Shi, Matsuyama, Fukuoka, Kobe, Tsukuba, Kanazawa
2019-08-09
Active, closed
Bristol-Myers Squibb
Phase 3
839
Nagoya, Chiba, Kashiwa-shi, Matsuyama, Fukuoka, Sapporo, Kanazawa, Kawasaki
2019-08-05
Active, closed
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms
DrugsE7386·Doxorubicin·Lenvatinib·Paclitaxel
Eisai Inc.
Phase 1/2
301
Nagoya, Toyoake, Kashiwa, Matsuyama, Kurume, Akashi, Kawasaki, Kamigyō-ku
2019-07-11
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Matsuyama, Nagoya, Niigata, Okayama, Tokushima, Tokyo
2019-07-09
Active, closed
Celgene
Phase 3
363
Matsuyama, Nagasaki, Sayama, Amagasaki-Shi, Fujisawa-Shi, Fukuoka, Hitachi, Ibaraki, Kamogawa
2019-01-02
Active, closed
AstraZeneca
Phase 2
401
Chūōku, Kanazawa, Kurume-shi,, Matsuyama, Nagoya, Sendai, Sunto-gun, Ube-shi
2018-12-21
Active, closed
AbbVie
Phase 2
270
Nagoya, Hirosaki-shi, Chiba, Matsuyama, Fukuoka, Kurume-shi, Fukuyama, Hiroshima
2018-10-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
3,500
Nagoya, Kashiwa, Matsuyama, Tōon, Kurume, Sapporo, Akashi, Himeji
2018-08-21
Active, closed
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
NCT03504397Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
DrugsFolinic acid·Zolbetuximab·Fluorouracil·Oxaliplatin
Astellas Pharma Global Development, Inc.
Phase 3
565
Nagoya, Kashiwa, Matsuyama, Sapporo, Kobe, Suita, Hidaka, Kitaadachi-gun
2018-06-21
Active, closed
AstraZeneca
Phase 3
1,018
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kita-gun, Koshigaya-shi, Kōtoku, Matsuyama
2018-05-14
Active, closed
AbbVie
Phase 2
156
Nagoya, Kamogawa-shi, Matsuyama, Gifu
2018-04-02
Active, closed
Janssen Research & Development, LLC
Phase 3
629
Chiba, Hirosaki, Kashiwa, Kita Gun, Kobe, Koshigaya, Matsuyama, Miyazaki
2018-03-23
Active, closed
Pfizer
Phase 3
1,054
Nagoya, Hirosaki, Kashiwa, Matsuyama, Kure, Sapporo, Kanazawa, Yokohama
2017-12-18
Active, closed
Hoffmann-La Roche
Phase 2/3
1,000
Bunkyō City, Fukuoka, Hiroshima, Ishikawa, Kanagawa, Kyoto, Matsuyama, Miyagi
2017-09-22
Active, closed
Eli Lilly and Company
Phase 3
5,637
Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Ōta, Hiroshima, Sapporo
2017-07-12
Active, closed
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS), Leukemia, Myeloid, Acute
DrugsIvosidenib·Azacitidine
Institut de Recherches Internationales Servier
Phase 3
146
Matsuyama, Fukui, Himeji, Kobe
2017-06-26
Active, closed
Pfizer
Phase 3
296
Nagoya, Matsuyama, Kurume, Sapporo, Kanazawa, Yokohama, Sendai, Osaka
2017-04-27
Active, closed
Ono Pharmaceutical Co., Ltd.
Phase 1
183
Nagoya, Toyoake, Kashiwa, Matsuyama, Fukuoka, Ōta, Sapporo, Yahaba-cho
2017-04-19
Active, closed
Acerta Pharma BV
Phase 3
635
Fukuoka, Kobe, Kyoto, Matsuyama, Nagoya, Osaka, Sapporo, Sendai
2017-04-05
Active, closed
Bristol-Myers Squibb
Phase 3
1,314
Hirosaki, Chiba, Matsuyama, Fukuoka, Sapporo, Tsukuba, Morioka, Kita-Gun
2017-03-24
Active, closed
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623Idiopathic Interstitial Pneumonia
North East Japan Study Group
Observational
867
Kiyosu, Nagoya, Seto, Toyoake, Hirosaki, Chiba, Kamogawa, Matsuyama
2016-12
Active, closed
Celgene
Phase 1/2
466
Matsuyama, Aomori, Hiroshima, Isehara City, Kanagawa, Kamogawa, Kyoto, Nagasaki, Nagoya
2016-10-14
Active, closed
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
NCT02864992Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
DrugTepotinib
EMD Serono Research & Development Institute, Inc.
Phase 2
337
Fukuoka, Kashiwa-shi, Kitaadachi-gun, Kurume-shi, Matsuyama, Nagoya, Niigata, Osaka
2016-09-13
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
1,052
Chūōku, Hakata-Ku, Koshigaya, Matsuyama, Minamiku, Miyazaki, Nagano, Nagasaki
2015-11-27
Active, closed
Hoffmann-La Roche
Phase 2
534
Aichi, Chūō, Hyōgo, Matsuyama, Miyagi, Niigata, Osaka, Shizuoka
2015-11-19
Active, closed
ETOP IBCSG Partners Foundation
Not applicable
518
Amagasaki, Hamamatsu, Fukuoka, Kagoshima, Kawasaki, Kyoto, Matsuyama, Minato-ku, Tokyo
2014-12-04
Active, closed
Aragon Pharmaceuticals, Inc.
Phase 3
982
Fukuoka, Kanazawa, Kashiwa, Kita-Gun, Kumamoto, Kurume, Matsuyama, Miyazaki
2014-11-26
Active, closed
Eli Lilly and Company
Phase 3
493
Nagoya, Chiba, Matsuyama, Sapporo, Nishinomiya, Yokohama, Niigata, Ōsaka-sayama
2014-11-06
Active, closed
Eli Lilly and Company
Phase 3
669
Nagoya, Chiba, Kashiwa, Matsuyama, Kurume, Sapporo, Nishinomiya, Kawasaki
2014-07-22
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
DrugOlaparib
AstraZeneca
Phase 3
327
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Osakasayama-shi, Sapporo
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
DrugOlaparib
AstraZeneca
Phase 3
450
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Sapporo, Sunto-gun
2013-08-26
Active, closed
NSABP Foundation Inc
Not applicable
1,636
Sendai, Sapporo, Akashi, Morioka, Gunma, Niigata, Matsuyama, Saitama
2013-08
Active, closed
AstraZeneca
Phase 2
162
Chūōku, Fukuoka, Matsuyama, Morioka, Shinjuku-ku, Yamagata, Yonago-shi
2010-02-04
Rows per page Showing 1–171 of 171
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/matsuyama

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 171 of those studies with a site in Matsuyama.

How many clinical trials are recruiting in Matsuyama?

67 of the 171 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 103 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Matsuyama), 171 studies
PhaseStudiesRecruitingShare
Phase 31214970.8%
Phase 220511.7%
Phase 11146.4%
Phase 1/2734.1%
Observational522.9%
Phase 2/3542.9%
Not applicable201.2%

Most active sponsors

Lead sponsors with the most studies (Matsuyama)
Lead sponsorStudiesRecruiting
AstraZeneca197
Merck Sharp & Dohme LLC199
Pfizer126
Amgen104
Bristol-Myers Squibb106
Daiichi Sankyo94
AbbVie82
Eli Lilly and Company81
BeOne Medicines64
Genmab60
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.